

# Zvi Raskin

Attorney at Law

1 Hillcrest Center Drive • Suite 230 • Spring Valley, New York 10977 • Tel: 845.391.0429  
E-mail: [zr@raskinlegal.com](mailto:zr@raskinlegal.com) • [www.raskinlegal.com](http://www.raskinlegal.com)

---

April 18, 2024

OTC Markets Group Inc.  
300 Vesey Street  
12th Floor  
New York, NY 10282

Dear Sir / Madam:

The undersigned is a U.S. resident engaged in the private practice of law. I am a member, in good standing, of the New York State Bar. I serve as securities counsel to International Star Inc. (the “Issuer”) and have been retained by the Issuer for the purpose of rendering this letter and related matters.

I am permitted to practice before the Securities and Exchange Commission (the “SEC”) and have not been prohibited from practice thereunder. I am not currently, nor have I been in the past five years, the subject of an investigation, hearing, or proceeding by the SEC, the U.S. Commodity Futures Trading Commission (CFTC), the Financial Industry Regulatory Authority (FINRA), or any other federal, state, or foreign regulatory agency. Furthermore, I am not currently, nor have I been in the past five years, suspended or barred from practicing in any state or jurisdiction, and/or charged in a civil or criminal case.

I do not own (beneficially or otherwise) any shares of the Issuer’s securities. I have not received and am not party to any agreement to receive in the future shares of the issuer’s stock in payment for services.

I have examined such corporate records and other documents and such questions of law as I considered necessary or appropriate for purposes of rendering the letter. This letter relates to the laws of the United States. As to matters of fact, I relied on information obtained from officers of the Issuer and other sources, but represent that all such sources were believed by me to be reliable.

In connection with the preparation of this letter, I reviewed the following documents (the “Information”) that are publicly available through the OTC Disclosure & News Service (together with the dates that such documents were posted):

Date Posted	Document Title
4/16/23	Annual Report - ILST 2023
11/20/23	Quarterly Report - ILST Q3 2023
8/29/23	Amended Quarterly Report – ILST Q2 2023
8/18/23	Quarterly Report - ILST Q2 2023
6/6/23	Amended Quarterly Report – ILST Q1 2023
5/22/23	Quarterly Report - ILST Q1 2023

In my opinion the Information: (i) constitutes “adequate current public information” concerning the Securities and the Issuer and “is available” within the meaning of Rule 144(c)(2) under the Securities Act; (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the “Exchange Act”); (iii) complies as to form with the OTC Markets Group’s Pink Basic Disclosure Guidelines, which are located on the Internet at [www.otcm Markets.com](http://www.otcm Markets.com); and (iv) has been posted through the OTC Disclosure & News Service.

The person responsible for preparing the financial statements contained in the Company’s 2023 Annual Report and in the Company’s Quarterly Reports for the First, Second and Third Quarters of 2023, all of which are unaudited, is David Natan, CPA, of Natan & Associates, LLC. He is a certified public accountant with significant experience and know-how regarding the preparation of financial statements.

The Issuer’s transfer agent is Clear Trust, LLC, and I confirm that the transfer agent is registered with the SEC. The method I used to confirm the number of outstanding shares set forth in the Information is: obtaining information from the Company’s Chief Executive Officer and reviewing current information provided by the Company’s stock transfer agent.

I have personally met with management and a majority of the directors of the Issuer, including Nochum Greenberg (a Director and Chairman of the Board, and the Company’s interim CEO during the period covered by the 2023 annual report) and Avi Minkowitz (a Director). I reviewed the Information, as amended, published by the Issuer through the OTC Disclosure & News Service and discussed the Information with each of the aforesaid individuals.

To the best of my knowledge, after inquiry of management and the Directors of the Issuer, none of the Issuer, its 5% holders, and/or its counsel is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.


Prior to February 14, 2023, the Issuer was a “shell company” as defined in Rules 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934. As of February 14, 2023, the Issuer completed its acquisition of Budding Equity Inc. In my opinion, upon the completion of that acquisition, the Issuer ceased to be a shell company.

The OTC Markets Group is entitled to rely on this letter in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933. However, no person other than OTC Markets Group is entitled to rely on the information set forth herein.

The OTC Markets Group has full and complete permission and rights to publish the letter through the OTC Disclosure & News Service for public viewing.

Thank you.

Very Truly Yours,



Zvi Raskin, Attorney at Law